KRAS and colorectal carcinoma: Conversely, in KRAS-mutant CRC cell lines, MEK inhibitors block MEK-ERK signaling, enhancing YAP nuclear accumulation and activating WNT target genes such as AXIN2, highlighting the intricate crosstalk between YAP and Wnt signaling in CRC progression (90).